Tonix Pharmaceuticals (NASDAQ:TNXP) Holding Corp. CEO Seth Lederman tells Proactive the clinical-stage biopharmaceutical company, has begun work at the company’s approximately 48,000 square foot research and development center in Frederick, Maryland, expecting to support the company’s expanding infectious disease pipeline. What's more, Lederman discussed its Phase 3 RELIEF Study results of TNX-102 SL to treat fibromyalgia.
Tonix begins work at its Infectious Disease R&D Center in Maryland, discusses RELIEF results
